StockData
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Travere Therapeutics, Inc.

Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$50.49+0.89 (+1.79%)

Close on Oct 19, 2026

Market cap
$4.72B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Oct 29, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2027
Ended Jun 30, 2026
Aug 4, 2026After market close$169.58M$-0.37$-0.10
Q1 FY2027
Ended Mar 31, 2026
May 4, 2026After market close$127.20M$-0.40$0.05
Q4 FY2026
Ended Dec 31, 2025
Feb 19, 2026After market close$129.69M$0.03$0.37
Q3 FY2026
Ended Sep 30, 2025
Oct 30, 2025After market close$164.90M$0.28$0.59
Q2 FY2026
Ended Jun 30, 2025
Aug 6, 2025After market close$114.40M$-0.14$0.13
Q1 FY2026
Ended Mar 31, 2025
May 1, 2025After market close$81.73M$-0.47$-0.19
Q4 FY2025
Ended Dec 31, 2024
Feb 20, 2025After market close$74.79M$-0.73$-0.47
Q3 FY2025
Ended Sep 30, 2024
Oct 31, 2024Before market open$62.90M$-0.70$-0.46
Q2 FY2025
Ended Jun 30, 2024
Aug 1, 2024After market close$54.10M$-0.91$-0.65
Q1 FY2025
Ended Mar 31, 2024
May 6, 2024After market close$41.37M$-1.76$-1.51
Q4 FY2024
Ended Dec 31, 2023
Feb 15, 2024After market close$45.06M$-1.18$0.94

Press releases

Announcements Travere Therapeutics filed with the SEC